Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Kidney Disease Stage V Clear all
Not listed Not applicable Interventional

A Single Arm sTudy to Evaluate the Effectiveness of EndoAVF in a Pre-dialysis Population (STEP Study)

NCT04633304
View directory record Official record
Conditions
CKD Stage 3, CKD Stage 4, CKD Stage 5
Interventions
EndoAVF System for endovascular AV fistula creation
Device
Lead sponsor
California Institute of Renal Research
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Jul 21, 2026, 11:08 AM EDT
Completed No phase listed Observational

Protein, Nutrition and Cardiovascular Disease in Stage 5 Chronic Kidney Disease

NCT00566670
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Nashville, Tennessee • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Jul 21, 2026, 11:08 AM EDT
Completed Phase 1 Interventional

Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)

NCT00792857
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTAP201 Injection, Doxercalciferol
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Peoria, Arizona • Springfield, Massachusetts • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Jul 21, 2026, 11:08 AM EDT
Completed Phase 2 Interventional Results available

Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients

NCT00660530
View directory record Official record
Conditions
Hyperphosphatemia, Kidney Disease
Interventions
Lanthanum Carbonate Chewable Product, Lanthanum carbonate crushed powder
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Jul 21, 2026, 11:08 AM EDT
Completed Not applicable Interventional

Exercise is Medicine for Patients With CKD

NCT03311763
View directory record Official record
Conditions
Chronic Kidney Disease stage4, Chronic Kidney Disease Stage V, Physical Activity
Interventions
EIM Fitness Practitioners, Counseling and wearable device
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
San Jose, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Jul 21, 2026, 11:08 AM EDT
Terminated Not applicable Interventional Results available

Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients

NCT03539861
View directory record Official record
Conditions
End Stage Renal Disease, Acute Kidney Injury, Chronic Kidney Disease Stage 5
Interventions
Hemodialysis
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Jul 21, 2026, 11:08 AM EDT
Enrolling by invitation Not applicable Interventional

Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease

NCT05514184
View directory record Official record
Conditions
Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), CKD Stage 3, CKD Stage 4, CKD Stage 5, Diabetes Mellitus, Diabetic Kidney Disease
Interventions
PLAFOND diet
Dietary Supplement
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Orange, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jul 21, 2026, 11:08 AM EDT
Completed Phase 4 Interventional

A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

NCT00463021
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Hectorol (doxercalciferol capsules), Zemplar (paricalcitol injection)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
8
States / cities
Downey, California • Paramount, California • Hudson, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Jul 21, 2026, 11:08 AM EDT
Completed Phase 3 Interventional

Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients

NCT00561093
View directory record Official record
Conditions
Hypoalbuminemia, Protein-energy Malnutrition, Inflammation, Oxidative Stress, Chronic Kidney Disease (CKD) Hemodialysis
Interventions
pentoxiphylline, Nepro, anti-inflammatory module (similar to Oxepa), Placebo pill imitating pentoxiphylline, Placebo to imitate Nepro, Placebo to imitate anti-inflammatory module (similar to Oxepa)
Drug · Dietary Supplement
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Irvine, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Jul 21, 2026, 11:08 AM EDT
Withdrawn Phase 3 Interventional

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

NCT02015780
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Fasiglifam, Placebo, Antihyperglycemic therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Jul 21, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Results available

Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

NCT00772382
View directory record Official record
Conditions
Chronic Kidney Disease, Dialysis, Hyperphosphatemia
Interventions
MCI-196
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • Tarzana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 21, 2026, 11:08 AM EDT
Completed Not applicable Interventional

Phosphate Kinetic Modeling

NCT01003223
View directory record Official record
Conditions
End Stage Renal Disease, Hyperphosphatemia
Interventions
Computer algorithm management of hyperphosphatemia
Other
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Jul 21, 2026, 11:08 AM EDT
Withdrawn Phase 4 Interventional

Evolocumab In Advanced Chronic Kidney Disease Trial

NCT04510844
View directory record Official record
Conditions
Chronic Kidney Diseases, High Cholesterol
Interventions
Evolocumab, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Mineola, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Jul 21, 2026, 11:08 AM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jul 21, 2026, 11:08 AM EDT
Terminated Not applicable Interventional Results available

A Pragmatic Approach to CKD Patient Education

NCT05138419
View directory record Official record
Conditions
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5, Patient Engagement
Interventions
CKD "What You Need To Know" Workbook System, CKD Action Plan, CKD Web-based Resource List, Food Label reading exercise
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 105 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 21, 2026, 11:08 AM EDT
Recruiting Not applicable Interventional

Kidney Transplant Improvement Through New Exercise Training to Increase Capacity

NCT07446296
View directory record Official record
Conditions
Chronic Kidney Disease 5D, Chronic Kidney Disease Stage 5, Kidney Failure, Kidney Failure,Chronic, Renal Insufficiency Chronic, Chronic Kidney Disease Stage 4, Kidney Transplantation, Waiting List, Transplant Candidate, Exercise Theraphy
Interventions
Exercise Rehabilitation Program with Physical Activity Tracker, Active control
Behavioral · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 21, 2026, 11:08 AM EDT
Completed Phase 2 Interventional

Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease

NCT00742716
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTA018 Injection
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Pembroke Pines, Florida • Meridian, Idaho • Springfield, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Jul 21, 2026, 11:08 AM EDT
Terminated Phase 3 Interventional Results available

A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

NCT00422513
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta, Epoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
44
States / cities
Birmingham, Alabama • Rainbow City, Alabama • Hot Springs, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2011 · Synced Jul 21, 2026, 11:08 AM EDT
Not listed No phase listed Observational

Malnutrition, Diet and Racial Disparities in Chronic Kidney Disease (CKD)

NCT01415570
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), End-Stage Renal Disease (ESRD)
Interventions
Not listed
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Jul 21, 2026, 11:08 AM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

NCT01764854
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease Stage 5, ESRD
Interventions
AZD1722 (in-patient), Placebo (in-patient), AZD1722 (out-patient), Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Tempe, Arizona • Denver, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Jul 21, 2026, 11:08 AM EDT
Completed Early Phase 1 Interventional

Pilot Randomized-controlled Trial of Integrated Palliative and Nephrology Care Versus Usual Nephrology Care.

NCT04520984
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Integrated ambulatory palliative and nephrology care, Standard nephrology care
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Jul 21, 2026, 11:08 AM EDT
Not yet recruiting Not applicable Interventional

The Agenda-Setting for Kidney Disease Open Pilot Trial

NCT07221604
View directory record Official record
Conditions
Chronic Kidney Disease Stage 4
Interventions
Chronic Kidney Disease Structured Agenda-Setting Tool
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Jul 21, 2026, 11:08 AM EDT
Terminated Phase 4 Interventional

Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis

NCT00062699
View directory record Official record
Conditions
End-Stage Kidney Disease
Interventions
Zemplar (paricalcitol injection), Calcijex
Drug
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
60
States / cities
Tuscaloosa, Alabama • Inglewood, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2006 · Synced Jul 21, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Results available

Head to Head Study Against Sevelamer Hydrochloride

NCT00441545
View directory record Official record
Conditions
Chronic Kidney Disease, Stage 5
Interventions
Fosrenol (Lanthanum Carbonate), Sevelamer hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
34
States / cities
Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jul 21, 2026, 11:08 AM EDT